Evidence map›Paper›PMID 37004177›Full record

ArticleRheumatology (Oxford, England)2023

Stratified genetic analysis reveals sex differences in MPO-ANCA-associated vasculitis.

Diana Ekman, Bengt Sennblad, Ann Knight, Åsa Karlsson, Solbritt Rantapää-Dahlqvist, Ewa Berglin, Bernd Stegmayr, Bo Baslund, Øyvind Palm, Hilde Haukeland and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 15 institutions in 5 countries.

Diana EkmanDepartment of Biochemistry and Biophysics, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Stockholm University, Sweden.
Bengt SennbladDepartment of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Ann KnightDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Åsa KarlssonScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Solbritt Rantapää-DahlqvistDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0001-8259-3863
Ewa BerglinDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Bernd StegmayrDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Bo BaslundCopenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Øyvind PalmDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.
Hilde HaukelandDepartment of Rheumatology, Martina Hansens Hospital, Gjettum, Norway.
Iva GunnarssonDepartment of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden.
Annette BruchfeldDepartment of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.ORCID 0000-0002-9752-9941
Mårten SegelmarkDepartment of Clinical Sciences, Division of Nephrology, Lund University and Skåne University Hospital, Lund, Sweden.
Sophie OhlssonDepartment of Clinical Sciences, Division of Nephrology, Lund University and Skåne University Hospital, Lund, Sweden.
Aladdin J MohammadDepartment of Clinical Sciences Lund, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.ORCID 0000-0002-7169-6936
Anna SvärdCenter for Clinical Research Dalarna, Uppsala University, Uppsala, Sweden.
Rille PulleritsDepartment of Rheumatology and Inflammation Research, Institution of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Hans HerlitzDepartment of Molecular and Clinical Medicine/Nephrology, Institute of Medicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Annika SöderberghDepartment of Rheumatology, Örebro University Hospital, Örebro, Sweden.
Roald OmdalClinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.
Roland JonssonBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Lars RönnblomDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Per ErikssonDepartment of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden.
Kerstin Lindblad-TohScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Johanna DahlqvistDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-6283-644X
Uppsala University · SELund University · SEUmeå University · SEBroad Institute · USLinköping University · SECopenhagen University Hospital · DKKarolinska University Hospital · SEMartina Hansens Hospital · NOÖrebro University Hospital · SEOslo University Hospital · NOSahlgrenska University Hospital · SEStavanger University Hospital · NOStockholm University · SEUniversity of Bergen · NOUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo identify and genetically characterize subgroups of patients with ANCA-associated vasculitides (AAV) based on sex and ANCA subtype.

methodsA previously established SNP dataset derived from DNA sequencing of 1853 genes and genotyping of 1088 Scandinavian cases with AAV and 1589 controls was stratified for sex and ANCA subtype and analysed for association with five top AAV SNPs. rs9274619, a lead variant at the HLA-DQB1/HLA-DQA2 locus previously associated with AAV positive for myeloperoxidase (MPO)-ANCA, was analysed for association with the cumulative disease involvement of ten different organ systems.

resultsrs9274619 showed a significantly stronger association to MPO-ANCA-positive females than males [P = 2.0 × 10-4, OR = 2.3 (95% CI 1.5, 3.5)], whereas proteinase 3 (PR3)-ANCA-associated variants rs1042335, rs9277341 (HLA-DPB1/A1) and rs28929474 (SERPINA1) were equally associated with females and males with PR3-ANCA. In MPO-ANCA-positive cases, carriers of the rs9274619 risk allele were more prone to disease engagement of eyes [P = 0.021, OR = 11 (95% CI 2.2, 205)] but less prone to pulmonary involvement [P = 0.026, OR = 0.52 (95% CI 0.30, 0.92)]. Moreover, AAV with both MPO-ANCA and PR3-ANCA was associated with the PR3-ANCA lead SNP rs1042335 [P = 0.0015, OR = 0.091 (95% CI 0.0022, 0.55)] but not with rs9274619.

conclusionsFemales and males with MPO-ANCA-positive AAV differ in genetic predisposition to disease, suggesting at least partially distinct disease mechanisms between the sexes. Double ANCA-positive AAV cases are genetically similar to PR3-ANCA-positive cases, providing clues to the clinical follow-up and treatment of these patients.

Indexed as

Antibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisFemaleHumansMaleMyeloblastinPeroxidaseSex CharacteristicsAntibodies, Antineutrophil CytoplasmicMyeloblastinPeroxidaseANCAANCA-associated vasculitissex differences

Identifiers

PMID37004177
PMCPMC10473270
OpenAlexW4362459723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.